| Literature DB >> 28845875 |
Pierluigi Russo1, Generoso Andria2, Alessandra Baldinelli3, Maria Lucia Boffi4, Emma Cerini5, Roberto Della Casa6, Andrea Imperatori7, Giovanni Battista Luciani8, Elisa Morra9, Rossella Parini10, Maurizio Pieroni11, Maria Antonia Prioli12, Luca Ragni13, Claudio Rapezzi14, Gabriele Rinelli15, Marta Rubino16, Cristiano Sarais17, Pietro Sciacca18, Francesco Seddio19, Giuseppe Limongelli20.
Abstract
Mucopolysaccharidoses (MPS) represent a group of rare lysosomal storage disorders, with a heterogeneous clinical presentation in terms of inheritance (autosomal and X-linked recessive), age of onset (infants, children, and adults), systemic and cardiac manifestations (mild to severe disease forms). Evidence-based recommendations on the diagnosis and management of cardiovascular disease in MPS are scarce. GICEM (Gruppo Italiano Cardiologi Esperti Malattie Metaboliche) is a group of cardiologists, cardiac surgeons and pediatricians with a specific expertise in metabolic diseases including MPS. In this paper, we report our experience and recommendations on the diagnosis and management of cardiovascular aspects in MPS, with a tailored approach based on current evidence, and taking into account MPS phenotype (particularly, I, II, IVa, VI), age at presentation, and severity of systemic and cardiac manifestations.Entities:
Mesh:
Year: 2017 PMID: 28845875 DOI: 10.1714/2741.27947
Source DB: PubMed Journal: G Ital Cardiol (Rome) ISSN: 1827-6806